1 FTSE 100 stock to buy and hold!

Jabran Khan discusses the past and recent performance of this healthcase sector stalwart, as well as the current favourable market conditions.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

FTSE 100 incumbent Smith & Nephew (LSE:SN) was impacted negatively by the pandemic. I believe it is primed to reap the benefits of reopening and should bounce back. Here’s why I’d add the shares to my holdings and keep hold of them.

Smith & Nephew shares drop

Smith & Nephew is a medical technology business that supports the healthcare sector to help return patients back to health and mobility. With a presence in over 100 countries, Smith & Nephew operates via three core segments. These are orthopaedics, sports medicine and ENT, and advanced wound management.

So what’s the latest with Smith and Nephew shares? Well, as I write, the shares are trading for 1,300p. At this time last year, the shares were trading for 1,539p, which is a 15% decline over a 12-month period.

FTSE 100 stocks have risks

At current levels, Smith & Nephew shares could be deemed expensive. The shares currently trade on a price-to-earnings ratio of 27. The index average is closer to 15. If the business were to report less than pleasing results or reveal any negative news, the shares could be affected negatively.

Many of Smith & Nephew’s products are used in elective procedures. When the pandemic struck, fighting the virus was the primary concern of the healthcare sector. Many procedures were cancelled and Smith & Nephew’s performance was affected. There is a real risk of new variants and restrictions linked to the pandemic, in my opinion. This could once more affect the kinds of procedures that use Smith & Nephew’s products being put on the back burner.

The positives and my verdict

So what are the positives? Well, I’ll start with performance. Smith & Nephew has a good track record of consistent performance. I do understand that past performance is not a guarantee of the future, however. Looking back, I can see revenue has reached £4.9bn for the three of the past four years, aside from 2020, which was impacted by the pandemic, when it recorded revenue of £4.5bn. Again, aside from 2020, profit increased year on year between 2018 and 2021.

Coming up to date, Smith & Nephew reported a favourable Q1 trading update at the end of April. It said that revenue was up by 3.3% compared to the same period last year. In addition to this, all segments had seen growth and established and emerging markets had also seen growth compared to Q1 2021.

SN shares would also boost my passive income stream as the company has a good record of dividend payments. The current dividend yield stands at 2.5%. This is below the FTSE 100 average yield of 3%-4% but I’m buoyed by the consistent record of payouts from Smith & Nephew. It has paid a consistent dividend since 1937! There aren’t many businesses that can attest to such a feat.

Finally, due to the issues during the height of the pandemic, I believe Smith & Nephew will benefit from pent up demand for elective procedures and its products. This should help boost performance and any returns.

I’d add Smith & Nephew shares to my holdings, thanks to its fantastic dividend record and recent performance growth.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jabran Khan has no position in any shares mentioned. The Motley Fool UK has recommended Smith & Nephew. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Female student sitting at the steps and using laptop
Investing Articles

Greggs shares: an outstanding bargain after crashing nearly 40%?

Shares of one-time market darling Greggs have been in foul form recently. But is this a once-in-a-blue-moon opportunity for our…

Read more »

Close-up of children holding a planet at the beach
Investing Articles

This FTSE 100 stock’s suddenly become the highest-yielder on the index!

The league table of FTSE 100 (INDEXFTSE:UKX) dividend stocks has a new number one. But our writer explains why there…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

Is this under-the-radar UK stock as cheap as its rooms?

Our writer’s been keeping an eye on a little-known UK stock that operates in a niche, but profitable, sector of…

Read more »

Young Caucasian woman holding up four fingers
Investing Articles

It’s a ‘Fabulous Friday’ for holders of these FTSE 100 shares!

Four members of the FTSE 100 (INDEXFTSE:UKX) are making their latest dividend payments today (11 July). Our writer takes a…

Read more »

Man riding the bus alone
Investing Articles

Check out this spectacular FTSE 250 stock

UK investors willing to look beyond the FTSE 100 can find some outstanding companies. Online advertising business Baltic Classifieds might…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

The JD Sports share price is down 18% in a year. And the stock’s only yielding 1.1%. Here’s what I’m doing…

With the JD Sports share price struggling and a tiny dividend on offer, there doesn’t appear to me much going…

Read more »

Passive and Active: text from letters of the wooden alphabet on a green chalk board
Investing Articles

How long would it take an owner of Legal & General shares to get their money back in passive income?

Our writer looks at the passive income potential of Legal & General, one of the highest-yielding shares on the FTSE…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Small but mighty: 2 FTSE 250 growth shares beating expectations

Mark Hartley picks out two lesser-known FTSE 250 shares delivering outstanding earnings growth – but with share prices that are…

Read more »